Viridax™ plans to bring forward a series of high value biopharmaceutical products based on the development of new and modified bacteriophage, including certain proprietary delivery technologies.

Viridax™ first products are being developed for the treatment of Staphylococcus aureus and other Staphylococcal spp. Additional bacteriophage are planned for the treatment of other bacterial agents.

Leading Product Candidate :

Staphylococcus aureus Bacteriophage :
( Respiratory & Systemic Infection Products ):
Staph Respiratory Infections
Staph Systemic Infections